Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prognostic factors in multiple myeloma].

A I Pick1, R Tamir, D Vana

  • 1Division of Clinical Immunology and Allergy, Beilinson Medical Center.

Harefuah
|April 15, 1990
PubMed
Summary

Prognostic factors for multiple myeloma (MM) survival are complex. Key indicators include age, hemoglobin, and specific protein levels, aiding personalized treatment strategies for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum intracellular adhesion molecule-1 (sicam-1) and soluble hla class-1 antigens in breast-cancer patients in relation to tumor burden.

Oncology reports·2011
Same author

Does mca contribute to the follow-up of breast-cancer patients by ca-15-3.

International journal of oncology·2011
Same author

Amplification of the expression of major histocompatibility class-I antigens by inducers of differentiation and gamma interferon in murine and human solid tumor-cell lines.

International journal of oncology·2011
Same author

Elevated pretreatment levels of soluble CD8 and Beta-2-microglobulin as indicators of relapse in breast-cancer patients.

International journal of oncology·2011
Same author

Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

British journal of cancer·2002
Same author

[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].

Voprosy onkologii·1999

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Context:

  • Multiple myeloma (MM) treatment has advanced, yet patient prognosis remains variable.
  • Survival duration in MM ranges significantly, necessitating accurate prognostic markers.
  • Early detection of disease activity is crucial for managing MM.

Purpose:

  • To identify prognostic parameters for multiple myeloma at diagnosis.
  • To evaluate factors influencing patient survival and quality of life in MM.
  • To explore the role of laboratory methods in detecting MM disease activity.

Summary:

  • This study identified age, hemoglobin, calcium, uric acid, Bence-Jones proteinuria, and polyclonal Ig concentrations as significant prognostic factors in MM.
  • Factors such as sex, WBC/platelet counts, BUN, M protein type, osteolytic lesions, and bone marrow plasma cell percentage were not found to be prognostically helpful.

Related Experiment Videos

  • Median survival was 42 months with good quality of life; peripheral blood findings are gaining importance due to improved laboratory methods.

    • Impact:

    • The findings aid in defining prognostic parameters at diagnosis for multiple myeloma patients.
    • Improved understanding of prognostic indicators can lead to more personalized treatment approaches.
    • Early detection of disease activity through sensitive lab methods may enhance MM patient survival.